ARTICLE SUMMARY:
Atrial fibrillation seems like the perfect medtech opportunity. But it’s been a frustrating effort for many start-ups and their investors. Acutus’ highly successful initial public offering this past August was over-subscribed, validating the confidence its executives and investors have placed in the company. Part 2 of a 2-part article
With a quarter of a billion dollars in capital raised and nearly a 10-year track record, Acutus Medical Inc. is hardly your typical medtech start-up. By 2017, six years after its founding, President and CEO Vince Burgess says, Acutus faced some fundamental questions. Should they look for an acquirer or was the opportunity large enough—and viable for a small company—to pursue on its own?
